Together with its partner Zelta by Merative, BSI Life Sciences announces the adoption of its Clinical Trial Management System (BSI CTMS) by Worldwide Clinical Trials.
Worldwide Clinical Trials is a full-service global contract research organization (CRO) that works in partnership with biotechnology and pharmaceutical companies to create customized solutions that advance new medications and is therapeutically focused on neuroscience, oncology, rare diseases, and cardiometabolic and inflammatory disease.
In 2023, Worldwide was named Most Innovative CRO by the Triangle Business Journal. Most recently, the CRO was recognized for excellence in all five categories in the 2024 CRO Leadership Awards, based on primary market research from Industry Standard Research (ISR) Reports. Within the ISR reports, Worldwide received several accolades from key decision-makers from small, midsize, and large biopharma companies for its Phase I and Phase II/III services, including being named the Highest Rated Phase I Provider for Overall User Preference and being ranked as the Top Phase II/III CRO for Overall Performance.
In January 2024, Worldwide selected BSI’s CTMS through their partnership with Zelta to handle their complex demands. The CRO needed a modern CTMS that would easily integrate with its Zelta EDC, as well as provide the highest usability and flexibility. Their goal was to transition all current studies for their active global trials as quickly and seamlessly as possible.
“At Worldwide, we partner with our customers to deliver top-tier clinical research that drives medical innovation and improves patient care,” says David Bowser, Executive Vice President and Chief Operating Officer of Worldwide Clinical Trials. “Our last system couldn’t keep up with our progress anymore. We knew we had to change to a state-of-the-art CTMS – We needed something that could integrate with our existing processes and migrate our ongoing trials as fast as possible. It’s hard to find a CTMS that works for CROs, but BSI CTMS has matched our needs.”
BSI CTMS is a leading eClinical software solution for CROs as well as for Pharma & Biotech, Med-Tech and SMO. With over 5,000 studies supported in more than 90 countries, BSI offers an intuitive system with an easy-to-use interface. As the CTMS is designed with the user in mind, training takes an average of a few hours.
The new partnership was also a triumph for Merative, who is acting as reseller of BSI CTMS with Worldwide Clinical Trials, in combination with Zelta’s clinical trials platform. Zelta works hand-in-hand with BSI CTMS, offering full and seamless integration throughout the suite. Worldwide’s success makes the perfect example of how the Zelta-BSI partnership supports portfolio-wide success.
“Today, clinical trial data management requires an ecosystem approach.” says Jennifer Duff, General Manager of Zelta. “The combined Worldwide, Zelta and BSI team was amazing – together we onboarded BSI CTMS with no problems and in less than 8 weeks from when we started the process.” she adds.
Jan Nielsen, BSI’s Community Manager of Life Sciences, is proud to work with Worldwide and Zelta. “We are delighted to welcome this exceptional CRO as a new customer and, together with Merative, look forward to supporting their continued success,” he says. “With its impressive reputation as a global industry leader, Worldwide Clinical Trials is a great addition to our network of CTMS users and partners in North America and beyond,” remarks Nielsen.
Worldwide Clinical Trials was able to go live with BSI CTMS at the end of March 2024, planning to complete their full trial migration by September. The CRO plans to make use of additional available CTMS modules and free annual upgrades to the latest product version. In continued collaboration with Merative, BSI will also provide ongoing, expert functional and technical support.
About Worldwide Clinical Trials:
Worldwide Clinical Trials (Worldwide) is a full-service global contract research organization (CRO) that works in partnership with biotechnology and pharmaceutical companies to create customized solutions that advance new medications – from discovery to reality. Worldwide’s capabilities include bioanalytical laboratory services, Phase I-IV clinical trials, and post-approval and real-world evidence studies – all powered by an accessible team of clinicians, scientists, and researchers who bring first-hand expertise and a collaborative, personalized approach to each clinical program. Worldwide is therapeutically focused on neuroscience, oncology, rare diseases, and cardiometabolic and inflammatory disease. Its global footprint spans nearly 60 countries with more than 3,500 team members. For more information, visit www.worldwide.com.
About Zelta:
Zelta by Merative is a clinical trials solution business that includes both a clinical data management and acquisition platform and consulting, enablement, and extension services. Zelta’s unified cloud-hosted platform has supported over 4,100 trials to date across all phases and complexities of research, including more than 500 phase III trials. Learn more at www.merative.com/clinical-development.
About BSI Life Sciences:
BSI Life Sciences offers smart eClinical software for CTMS, eTMF and more. BSI makes life science software for people – and has done so for 27+ years. BSI’s software solutions are made in Switzerland, Germany, USA, and anywhere else clients need them to be. They’re both innovative and user-friendly.
BSI focuses its resources on staying ahead of the trends and delivering functional, compliant, and affordable eClinical software. With this mission, BSI helps its customers continuously optimize and accelerate the clinical development process.
For more information, please visit: www.bsi-lifesciences.com
Worldwide Clinical Trials is a full-service global contract research organization (CRO) that works in partnership with biotechnology and pharmaceutical companies to create customized solutions that advance new medications and is therapeutically focused on neuroscience, oncology, rare diseases, and cardiometabolic and inflammatory disease.
In 2023, Worldwide was named Most Innovative CRO by the Triangle Business Journal. Most recently, the CRO was recognized for excellence in all five categories in the 2024 CRO Leadership Awards, based on primary market research from Industry Standard Research (ISR) Reports. Within the ISR reports, Worldwide received several accolades from key decision-makers from small, midsize, and large biopharma companies for its Phase I and Phase II/III services, including being named the Highest Rated Phase I Provider for Overall User Preference and being ranked as the Top Phase II/III CRO for Overall Performance.
In January 2024, Worldwide selected BSI’s CTMS through their partnership with Zelta to handle their complex demands. The CRO needed a modern CTMS that would easily integrate with its Zelta EDC, as well as provide the highest usability and flexibility. Their goal was to transition all current studies for their active global trials as quickly and seamlessly as possible.
“At Worldwide, we partner with our customers to deliver top-tier clinical research that drives medical innovation and improves patient care,” says David Bowser, Executive Vice President and Chief Operating Officer of Worldwide Clinical Trials. “Our last system couldn’t keep up with our progress anymore. We knew we had to change to a state-of-the-art CTMS – We needed something that could integrate with our existing processes and migrate our ongoing trials as fast as possible. It’s hard to find a CTMS that works for CROs, but BSI CTMS has matched our needs.”
BSI CTMS is a leading eClinical software solution for CROs as well as for Pharma & Biotech, Med-Tech and SMO. With over 5,000 studies supported in more than 90 countries, BSI offers an intuitive system with an easy-to-use interface. As the CTMS is designed with the user in mind, training takes an average of a few hours.
The new partnership was also a triumph for Merative, who is acting as reseller of BSI CTMS with Worldwide Clinical Trials, in combination with Zelta’s clinical trials platform. Zelta works hand-in-hand with BSI CTMS, offering full and seamless integration throughout the suite. Worldwide’s success makes the perfect example of how the Zelta-BSI partnership supports portfolio-wide success.
“Today, clinical trial data management requires an ecosystem approach.” says Jennifer Duff, General Manager of Zelta. “The combined Worldwide, Zelta and BSI team was amazing – together we onboarded BSI CTMS with no problems and in less than 8 weeks from when we started the process.” she adds.
Jan Nielsen, BSI’s Community Manager of Life Sciences, is proud to work with Worldwide and Zelta. “We are delighted to welcome this exceptional CRO as a new customer and, together with Merative, look forward to supporting their continued success,” he says. “With its impressive reputation as a global industry leader, Worldwide Clinical Trials is a great addition to our network of CTMS users and partners in North America and beyond,” remarks Nielsen.
Worldwide Clinical Trials was able to go live with BSI CTMS at the end of March 2024, planning to complete their full trial migration by September. The CRO plans to make use of additional available CTMS modules and free annual upgrades to the latest product version. In continued collaboration with Merative, BSI will also provide ongoing, expert functional and technical support.
About Worldwide Clinical Trials:
Worldwide Clinical Trials (Worldwide) is a full-service global contract research organization (CRO) that works in partnership with biotechnology and pharmaceutical companies to create customized solutions that advance new medications – from discovery to reality. Worldwide’s capabilities include bioanalytical laboratory services, Phase I-IV clinical trials, and post-approval and real-world evidence studies – all powered by an accessible team of clinicians, scientists, and researchers who bring first-hand expertise and a collaborative, personalized approach to each clinical program. Worldwide is therapeutically focused on neuroscience, oncology, rare diseases, and cardiometabolic and inflammatory disease. Its global footprint spans nearly 60 countries with more than 3,500 team members. For more information, visit www.worldwide.com.
About Zelta:
Zelta by Merative is a clinical trials solution business that includes both a clinical data management and acquisition platform and consulting, enablement, and extension services. Zelta’s unified cloud-hosted platform has supported over 4,100 trials to date across all phases and complexities of research, including more than 500 phase III trials. Learn more at www.merative.com/clinical-development.
About BSI Life Sciences:
BSI Life Sciences offers smart eClinical software for CTMS, eTMF and more. BSI makes life science software for people – and has done so for 27+ years. BSI’s software solutions are made in Switzerland, Germany, USA, and anywhere else clients need them to be. They’re both innovative and user-friendly.
BSI focuses its resources on staying ahead of the trends and delivering functional, compliant, and affordable eClinical software. With this mission, BSI helps its customers continuously optimize and accelerate the clinical development process.
For more information, please visit: www.bsi-lifesciences.com
